← Back to Screener
Aligos Therapeutics, Inc. Common Stock (ALGS)
Price$6.51
Favorite Metrics
Price vs S&P 500 (26W)-37.91%
Price vs S&P 500 (4W)-11.40%
Market Capitalization$41.33M
All Metrics
Book Value / Share (Quarterly)$8.67
P/TBV (Annual)0.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-46.04%
Cash Flow / Share (Quarterly)$-13.42
Price vs S&P 500 (YTD)-32.46%
Net Profit Margin (TTM)-1106.72%
EPS (TTM)$-1.54
10-Day Avg Trading Volume0.72M
EPS Excl Extra (TTM)$-1.54
EPS (Annual)$-2.45
ROI (Annual)-45.06%
Net Profit Margin (5Y Avg)-1726.24%
Cash / Share (Quarterly)$12.60
Revenue Growth QoQ (YoY)-73.13%
ROA (Last FY)-27.33%
Revenue Growth TTM (YoY)-44.59%
EBITD / Share (TTM)$-2.52
ROE (5Y Avg)-70.33%
Operating Margin (TTM)-4024.93%
Cash Flow / Share (Annual)$-13.42
P/B Ratio0.77x
P/B Ratio (Quarterly)1.07x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)10.60x
ROA (TTM)-20.01%
EPS Incl Extra (Annual)$-2.45
Current Ratio (Annual)3.90x
Quick Ratio (Quarterly)3.90x
3-Month Avg Trading Volume0.13M
52-Week Price Return46.17%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.26
P/S Ratio (Annual)18.91x
Asset Turnover (Annual)0.02x
52-Week High$13.69
Operating Margin (5Y Avg)-2099.40%
EPS Excl Extra (Annual)$-2.45
CapEx CAGR (5Y)-26.66%
26-Week Price Return-29.16%
Quick Ratio (Annual)3.90x
13-Week Price Return-26.19%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.90x
Enterprise Value$23.177
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1092.36%
Cash / Share (Annual)$12.60
3-Month Return Std Dev81.70%
Net Income / Employee (TTM)$-0
ROE (Last FY)-45.18%
EPS Basic Excl Extra (Annual)$-2.45
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.54
ROI (TTM)-28.11%
P/S Ratio (TTM)18.91x
Pretax Margin (5Y Avg)-1719.87%
Revenue / Share (Annual)$0.22
Tangible BV / Share (Annual)$2.42
Price vs S&P 500 (52W)11.08%
Year-to-Date Return-28.33%
5-Day Price Return-22.69%
EPS Normalized (Annual)$-2.45
ROA (5Y Avg)-78.47%
Net Profit Margin (Annual)-1106.72%
Month-to-Date Return-10.09%
Cash Flow / Share (TTM)$-1.86
EBITD / Share (Annual)$-2.54
Operating Margin (Annual)-4024.93%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-70.14%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.54
P/TBV (Quarterly)0.98x
P/B Ratio (Annual)1.07x
Pretax Margin (TTM)-1092.36%
Book Value / Share (Annual)$8.67
Price vs S&P 500 (13W)-29.05%
Beta2.48x
Revenue / Share (TTM)$0.21
ROE (TTM)-28.16%
52-Week Low$4.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.18
4.18
4.18
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALGSAligos Therapeutics, Inc. Common Stock | 18.91x | -44.59% | — | — | $6.51 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 11.09x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for viral and liver diseases, including chronic hepatitis B, coronaviruses, and nonalcoholic steatohepatitis (NASH). The company maintains a pipeline of drug candidates targeting these areas of significant unmet medical need.